Finance

Lists
Q3 2026 earnings • released • EPS beat +25.00% • Revenue beat +13.45%
See results
NAUT:NASDAQ
Nautilus Biotechnology Inc
$2.73
-13.06%
(-0.41) 1D
$2.75
+0.73% (+0.020)
After hours
Closed: Oct 30, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAUT...
Open
$2.88
High
$3.08
Low
$2.64
Mkt. cap
347.73M
Avg. vol.
10.15M
Volume
8.07M
52-wk high
$4.31
52-wk low
$0.84
EPS
-$0.46
Beta
0.73
Shares outstanding
127.37M
No. of employees
127
Open
$2.88
High
$3.08
Low
$2.64
Mkt. cap
347.73M
Avg. vol.
10.15M
Volume
8.07M
52-wk high
$4.31
52-wk low
$0.84
EPS
-$0.46
Beta
0.73
Shares outstanding
127.37M
No. of employees
127
News stories
From web sources and news partners
About Nautilus Biotechnology Inc
CEO-
Employees127
Founded2016
HeadquartersSeattle, Washington, United States
SectorHealth care
Websitenautilus.bio
Analyst ratings
Based on 3 analysts giving stock ratings to NAUT in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NAUT in the last 3 months.
Highest
Current $2.73
$4.00 (+46.52%)
Average
$4.00 (+46.52%)
Lowest
$4.00 (+46.52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Max Masucci
Roth MKM
Buy
Maintained
$4.00
+46.5%
10/28/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$4.00
+46.5%
10/27/2026
Unknown Analyst
Leerink Partners
Buy
Initiated
$4.00
+46.5%
09/09/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
$4.00
+46.5%
07/28/2026
Daniel Brennan
TD Cowen
Buy
Maintained
-
-
04/28/2026
Last report
Oct 27, 2026
Fiscal period
Q3 2026
-$0.12 / -$0.16
+25.00%beat
Revenue / Est. (USD)
234.00K / 206.25K
+13.45%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
190.00K
Cost of goods sold
-
-
-
15.00K
Cost of revenue
-
-
-
15.00K
Research and development expenses
9.60M
9.58M
9.71M
9.61M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.87M
5.85M
6.42M
6.32M
Operating expense
15.47M
15.42M
16.12M
15.94M
Total operating expenses
15.47M
15.42M
16.12M
15.95M
Operating income
-15.47M
-15.42M
-16.12M
-15.76M
Other non operating income
-5.00K
-145.00K
-15.00K
-13.00K
EBT including unusual items
-13.57M
-13.78M
-14.70M
-14.47M
EBT excluding unusual items
-13.57M
-13.92M
-14.70M
-14.47M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13.57M
-13.78M
-14.70M
-14.47M
Net profit margin
-
-
-
-7,615.26%
Earnings per share
-
-
-
-
Interest and investment income
1.90M
1.65M
1.44M
1.31M
Interest expense
-
-
-
-
Net interest expenses
1.90M
1.65M
1.44M
1.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.05M
-15.02M
-15.79M
-15.49M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps